Lobular Carcinoma in situ (LCIS) and Ductal Carcinoma in situ (DCIS) are abnormalities that doctors call “stage zero” breast cancer. Women with either of these diagnoses often ask us, “Do I have breast cancer?”
Despite the fact that its name includes the term “carcinoma,” LCIS is not a true breast cancer. Rather, LCIS is an indication that a person is at higher-than-average risk for getting breast cancer at some point in the future. For this reason, some experts prefer the term “lobular neoplasia” instead of “lobular carcinoma.” A neoplasia is a collection of abnormal cells. LCIS is restricted to the lobules.
DCIS is the most common kind of carcinoma (cancer) in situ. In DCIS, cancer cells are only in the ductal walls. If DCIS is not treated, it will likely grow into an invasive cancer. Here is a side-by-side comparison of the two conditions:
Ask your doctor questions about your diagnosis and your pathology results. You and your doctor will decide what treatment is best for your situation. Whether you are diagnosed with LCIS or DCIS, it can be overwhelming. Get support when needed. Don’t be afraid to ask for help or to turn to a trusted friend when you need to share your feelings and concerns. Make healthy changes to your lifestyle, so you can feel your best.
U-M Comprehensive Cancer Center News: Yearly mammograms from age 40 save 71 percent more lives, study shows
National Comprehensive Cancer Center Guidelines for Patients™: Breast Cancer
The Cancer AnswerLine™ is a dedicated phone line at the Comprehensive Cancer Center that is staffed by oncology nurses five days a week, 8 a.m. – 5:30 p.m. at 800-865-1125. They have a combined 105 years of experience helping patients and their families who have questions about cancer.
The University of Michigan Comprehensive Cancer Center’s 1,000 doctors, nurses, care givers and researchers are united by one thought: to deliver the highest quality, compassionate care while working to conquer cancer through innovation and collaboration. The center is among the top-ranked national cancer programs, and #1 in Michigan for cancer patient care. Seventeen multidisciplinary clinics offer one-stop access to teams of specialists for personalized treatment plans, part of the ideal patient care experience. Patients also benefit through access to promising new cancer therapies.